Rationale: Antibody-targeted delivery of imaging agents can enhance the sensitivity and accuracy of current imaging techniques. Similarly, homing of effector cells to disease sites increases the efficacy of regenerative cell therapy while reducing the number of cells required. Currently, targeting can be achieved via chemical conjugation to specific antibodies, which typically results in the loss of antibody functionality and in severe cell damage. An ideal conjugation technique should ensure retention of antigen-binding activity and functionality of the targeted biological component.
T argeted delivery increases the efficacy of drugs and regenerative cell therapy, reduces the dose required, and consequently minimizes potential negative side effects. Similarly, targeted delivery of imaging agents can localize and retain contrast at disease sites, enhancing the sensitivity and accuracy of current imaging techniques. Targeting can be achieved via conjugation to antibodies that possess a number of functional groups, such as amine, thiol, and carboxylate groups suitable for chemical conjugation purposes. 1 Most antibody conjugation methods target endogenous amino acids, such as the amino group of lysine or the thiol group of cysteine 2 ; however, these groups are commonly distributed throughout the antibody structure. If the conjugation involves critical residues essential for antigen binding, the functionality of antibodies, particularly small recombinant antibody fragments, will be impaired. Conjugation can also take place by use of the carbohydrate chains typically attached to the constant heavy chain domain within the crystallizable fragment region of the antibody 3 ; however, this method is limited to glycosylated antibodies. Furthermore, conventional bioconjugation typically leads to multicomponent heterogenous mixtures that are incapable of complying with regulatory requirements. Overall, a single and covalent bond between an antibody and a conjugation partner that preserves the functionality of both components is of critical importance and has a multitude of potential applications in the field of diagnostic and therapeutic antibody development.
Current coupling approaches for site-specific conjugation are based on the introduction of unique functional groups such as ketones and azides into proteins not present in natural amino acids. They can be incorporated into proteins by chemical modification of the N-terminus of the protein, 4 by unnatural amino acid mutagenesis, 5 or by the use of enzymes that transfer prosthetic groups to proteins. 6 However, these methods face practical limitations in terms of feasibility, scalability, and efficacy. 7 In the present study, we demonstrate a new chemoenzymatic method to conjugate a single-chain antibody (scFv) to enhanced green fluorescent protein (eGFP), Chinese hamster ovarian (CHO) cells, human cord blood mononuclear cells, and microparticles of iron oxide (MPIOs) in a site-specific manner. This procedure uses Staphylococcus aureus enzyme sortase A, an enzyme that recognizes diverse substrates via an LPXTG motif, and conjugates this tag to a polyglycine nucleophile. 8 We engineered an LPETG-tagged scFv targeted to ligand-induced binding sites (LIBS) on glycoprotein (GP) IIb/IIIa (CD41/CD61) receptors, the most highly expressed molecules on the surface of activated platelets and critical players in atherosclerosis, thrombosis, and inflammation. 9, 10 The conjugation method described in the present report comprises 2 stages: (1) the introduction of GGG peptides (as sortase nucleophiles) to the surface of magnetic particles and cells by a series of chemical reactions, and (2) the incubation of triglycine-tagged components with the sortase A enzyme and anti-LIBS scFv (Figure 1 ).
We demonstrate this novel use of sortase A for the selective labeling of imaging contrast particles and live cells with scFvs suitable for targeted molecular imaging and cell homing. This method is universally applicable and is particularly suitable for the antibody "tagging" of proteins, particles, or cells.
Generation and Production of Proteins
The generation of the anti-LIBS scFv from a hybridoma cell line that expresses a monoclonal antibody against LIBS epitopes on GP IIb/IIIa has been described previously. 11 The LPETG motif was introduced to the C-terminal end of anti-LIBS scFv, and the scFv was subcloned into a pMT vector (Invitrogen, Carlsbad, CA) for expression in insect cells (Invitrogen). The GGG motif was introduced to the N-terminal end of the eGFP sequence by polymerase chain reaction, and GGG-eGFP was expressed in BL21-DE3 Escherichia coli (New England Biolabs, Ipswich, MA). The generation of the plasmid construct Staphylococcus aureus sortase 8 and the expression and production of soluble sortase A 12 were described previously.
Conjugation of Anti-LIBS to GGG-eGFP, Amine-Tagged Iron Oxide Particles, and Cells
The overall eGFP and particle-coupling procedures are summarized in Figures 1A and 1B , respectively. Anti-LIBS-LPETG scFv was coupled onto the cell surface by 2 methods. In the first
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Chinese hamster ovary LIBS ligand-induced binding sites MPIO microparticles of iron oxide scFv single-chain antibody Figure 1 . Image illustrating the coupling procedures of eGFP, MPIOs, and CHO cells with anti-LIBS-LPETG. A, eGFP: Sortase A catalyzed a condensation reaction between a C-terminal-LPETG tag on the GP IIb/IIIa-targeting single-chain antibody (anti-LIBS) and a triglycine (GGG) bridge on the eGFP protein. B, MPIO: tert-butyloxycarbonyl-protected GGGWW peptides were introduced onto amine particles via carboxyl activation. After deprotection, a sortase-mediated condensation reaction between anti-LIBS LPETG and GGG particles was performed. C, CHO cell: Protocol A comprised the sortase-catalyzed reaction between anti-LIBS LPETG and amine groups of the cell surface. Protocol B included the thiolation of cell membrane amine groups (sulfhydryl addition), the introduction of GGG maleimide on the cell surface via the reaction between the sulfhydryl (-SH) groups and the maleimide groups, and covalent coupling between anti-LIBS LPETG and GGG groups on the cell membrane via the sortase-mediated reaction.
method, only 1 step was used. In the second method, 3 steps were used. The overall cell-coupling procedures are summarized in Figure 1C . The efficiency of the coupling procedure was analyzed by SDS-PAGE.
Flow Cytometry
Blood from healthy volunteers taking no medication was collected by venipuncture, anticoagulated with citric acid, and centrifuged to collect platelet-rich plasma. Diluted platelet-rich plasma was either activated by 20 mol/L ADP (Sigma, St. Louis, MO) or nonactivated and incubated with different concentrations of the coupled anti-LIBS-eGFP products. Samples were fixed and analyzed by FACSCalibur (BD Biosciences, San Jose, CA).
Static Adhesion Assays
Glass coverslips were coated with either gel-filtered platelets or purified platelets and then incubated with predetermined numbers of either nontargeted or targeted products. Coverslips were then washed and fixed with CellFIX (BD Biosciences). Differential interference contrast/fluorescence images were taken at 600ϫ or 200ϫ magnification with an inverted microscope (IX81; Olympus, Tokyo, Japan) with a digital black-and-white camera (XM10; Olympus) and CellP 1692 (AnalySIS Image Processing; Olympus) software. Binding particles/cells were quantified with ImageJ (NIH, Bethesda, MD) software (nϭ6).
Flow Chamber Assays
Glass capillaries were coated with collagen-1 and then blocked with BSA (both, Sigma). Blood was taken from healthy donors, citrated, and perfused through the capillary for 5 minutes to allow the formation of thrombi. After washing, particles (Invitrogen) or cells (3ϫ10 6 particles or cells per milliliter) were perfused through the capillary for 5 minutes at different shear rates ranging from 100 to 1500 s Ϫ1 . Movies/images were taken at 200ϫ magnification with the above-described optics system. Thrombi were specifically stained with PAC-1-FITC or CD62P-PE (BD Biosciences). Binding particles or cells were quantified with ImageJ (NIH) software (nϭ3).
Intravital Studies
C57BL/6 wild-type mice (weight 15 to 17 g) were anesthetized by ketamine/xylazine (Bayer, Leverkusen, Germany). The injury of arteries/veins was induced by a microdrop of 10% FeCl 3 (Sigma). When the thrombus began to build up, predetermined amounts of particles or CHO cells were injected via a jugular vein cannula (nϭ3). Movies and images of the thrombus were taken before, during, and after injection at 200ϫ magnification with the abovedescribed optics system. Particles were seen by their TRITC autofluorescence, and CHO cells were visualized by CellTracker Green CMFDA dye (Invitrogen).
Magnetic Resonance Imaging Experiments and Histology
C57BL/6 wild-type mice were anesthetized, and carotid arterial wall-adherent thrombosis was induced with 6% ferrous chloride (Sigma). A total of 4ϫ10 8 MPIOs (Invitrogen) was injected via tail vein. Magnetic resonance imaging (MRI) and histology procedures were conducted as described previously. 13
Statistical Analysis
Results are presented as meanϮSD. Data were analyzed for statistical significance with the 1-tailed paired t test. The data were checked for normal distribution by Kolmogorov-Smirnov normality test. Where normal distribution could not be detected, a nonparametric Mann Whitney 1-tailed test was applied. PՅ0.05 was considered significant.
Results
Characterization and Optimization of Sortase-Mediated Coupling With scFvs
First, eGFP was selected as a model substrate to establish optimal enzymatic reaction conditions for the coupling to anti-LIBS scFv, an scFv directed against LIBS on GP IIb/IIIa. Figure 2A demonstrates the formation of scFv-eGFP via sortase A enzyme coupling. Optimization of the reaction conditions enabled maximization of the coupled product yield while making the most efficient use of substrate materials. These included variations in CaCl 2 , substrate, and enzyme concentrations. Sortase A is a calcium-dependent transpeptidase that requires the presence of free calcium ions for its coupling activity; however, it was observed that in the presence of calcium, the scFv became insoluble in a dose-dependent manner, which caused it to precipitate and reduced its availability for coupling. Increasing concentrations of CaCl 2 formed progressively less coupled product, as evidenced by the diminishing 61-kDa band at higher concentrations of calcium (Online Figure I, A) . At 0.5 mmol/L, we found no detectable evidence of precipitation and consequently a much higher amount of coupled product. A nearly proportional relationship between scFv concentration and coupled construct formation was also demonstrated (Online Figure I, B ). Notably, there was little effect on the amount of coupled construct produced by increasing the concentration of the GGG-eGFP (Online Figure I, C). Online Figure I , D suggests that an increase in sortase concentration can improve the yield of the coupled product; however, this appeared to plateau beyond 5 to 10 mol/L. Taken together, these results suggest that 0.5 mmol/L CaCl 2 and 10 mol/L sortase are optimal parameters for the sortase-mediated reaction. We demonstrated the retained functionality of the scFv after sortase-mediated coupling to the eGFP molecule in a flow cytometric analysis ( Figure 2B ). Figures 2C and 2D show the selective binding of the scFv-eGFP construct to activated platelets adhered to fibrinogen-coated glass coverslips. Activated platelets were stained with the coupled product and visualized by fluorescence microscopy. These results indicate the preserved specific targeting of the scFv after the conjugation process.
Conjugation of Anti-LIBS LPETG to Amine-Tagged Iron Oxide Microparticles and the Specific Binding of the Coupled Particles to Activated Platelets In Vitro
Next, we investigated the conjugation of anti-LIBS scFv to iron oxide particles using sortase and assessed the efficacy by gel electrophoresis. We found that anti-LIBS could be specifically conjugated onto particles at a yield of 0.21Ϯ0.015 pg of anti-LIBS per particle (nϭ3; Online Figure II , Ac). Approximately 70% of the anti-LIBS amount in the reaction was successfully coupled to the particles. In the absence of sortase A, the nonspecific binding of scFv to particles was significantly lower than the specific binding in the presence of sortase A (Online Figure II , Ab). The results demonstrated the specific catalytic activity of sortase A in the condensation reaction between anti-LIBS LPETG and GGG particles.
In adhesion assays, anti-LIBS particles bound specifically to activated GP IIb/IIIa receptors on platelets. Online Figure II , B shows the significantly higher numbers of scFv-coupled particles binding on activated platelets compared with noncoupled particles (GGG particles). Increasing the number of particles incubated resulted in higher numbers of binding particles. Online Figure II , D illustrates the near absence of the binding of the nontargeting particles, whereas online Figure II, C demonstrates a large number of anti-LIBS particles binding to a single layer of activated platelets. Online Figure III represents the preserved functionality of anti-LIBS scFv and the preserved binding of targeted beads during storage at 4°C. The obtained data indicate the feasibility for storage of the targeted imaging agents for longer time periods.
Targeted Binding of Coupled Particles to Thrombi Under Flow Conditions
The adhesion of anti-LIBS-coupled particles to in vitro thrombi under shear stress was assessed in a flow chamber system ( Figure 3 ). Shear stress was varied from 100 s Ϫ1 (venous flow) to 1500 s Ϫ1 (arterial flow). At both venous and arterial flows, the number of adherent coupled particles was significantly higher than that of noncoupled particles. Online Videos 1 and 2 show binding of particles at a shear stress of 500 s Ϫ1 .
To investigate the targeting ability of anti-LIBS particles in vivo, we used intravital imaging via differential interference contrast and fluorescence microscopy to directly visualize the binding of particles (orange autofluorescence) to thrombi in the observed artery. For each animal, 25ϫ10 6 of either anti-LIBS or GGG particles was administered. The number of anti-LIBS-coupled particles adhering to the thrombi was significantly higher than that of the control GGG particles. Immediately after injection, anti-LIBS particles were found along the surface of the thrombus. As seen in Figure 4B and Online Video 4, a large number of targeted particles were attached to the thrombi, whereas only 1 control particle was found in Figure 4A and Online Video 3. We tested the effect of particles on thrombus formation by injecting the targeted constructs before the induction of thrombi and did not see an effect on thrombus formation. We also observed that in contrast to the postinjury injections, in which the constructs bound to the thrombus surface, in the preinjury injections, the contrast particles incorporated in the thrombus (Online Figures IV and V) . To provide proof of concept for the suitability of our tagging approach for MRI, we performed in vivo MRI experiments using 1 m of MPIOs because of their proven excellent magnetic resonance contrast properties as shown in previous reports from our group. [13] [14] [15] With these tagged particles, we could demonstrate excellent magnetic resonance signals in vivo (Online Figure VI) . Histological analysis of the injured carotid artery demonstrated MPIOs that bound on the induced thrombus, which occupied approximately 20% of the vessel lumen (Online Figure VII) .
Cell Anti-LIBS Conjugation and Functional Assessment in Static Adhesion Assay
The above procedure was adapted to the coupling of scFv to cells to assign unique and generally applicable targeting properties to cells. This approach is composed of 3 steps, described in protocol B in Figure 1C . Parameters in steps 1 and 2 were optimized by use of near-infrared DyLight 800 maleimide instead of NH 2 -GGG-maleimide peptide, whereas optimal parameters in step 3 were determined by use of eGFP-LPETG instead of anti-LIBS LPETG. We used a reaction that contained cells without GGG tags, eGFP-LPETG, and sortase A as a negative control. Interestingly, we found that eGFP-LPETG was successfully coupled to CHO cells in the absence of the GGG groups (Online Figure VIII) . The flow histograms of cells from this control reaction detected considerably more fluorescence than those incubated without sortase A. This finding suggested another cell-labeling method, which is described as protocol A in Figure 1C ; however, its efficiency was significantly lower than that in protocol B, which comprised the full 3 steps (Online Figure VIII) . It is possible that free amine groups on cell surface receptors function as a nucleophile for the enzyme, although the acyl-enzyme intermediate is less reactive toward an alkylamine than toward GGG or Gly n . Parthasarathy et al 12 also reported the conjugation of eGFP-LPETG to amine-tagged particles and amine-terminated poly(ethylene) glycol by the sortase A enzyme. Overall, the successful labeling of eGFP on CHO cell surfaces provides proof of concept for the coupling of scFv onto cells.
Gel electrophoresis analysis of the reaction mixture (Online Figure IX, A) revealed that the average coupling efficiency was 10.08Ϯ3.15 pg (nϭ3) of anti-LIBS per CHO cell in protocol B, a 2-fold increase compared with that in protocol A. In static adhesion assays, the binding of the scFv-conjugated cells from both protocols was significantly stronger than the control (GGG) cells (Online Figure IX , B and C). The degree of binding increased with higher cell numbers in a dose-dependent manner. Notably, the binding efficiency of anti-LIBS-conjugated cells from protocol B was 5-to 7-fold higher than that produced by protocol A, which indicates the successful immobilization of a higher number of scFvs on the cell surface for targeting.
Targeting of Anti-LIBS Cells to Thrombi Under Shear Conditions
Anti-LIBS-coupled CHO cells from protocol B were investigated further in flow experiments under different shear rates. After targeted cells were perfused through a platelet-coated capillary at 100 s Ϫ1 for 5 minutes, approximately 400 cells/mm 2 platelet aggregates were immobilized ( Figure 5 ; Online Video 5), whereas fewer than 10 nontargeted cells bound to a unit area (mm 2 ) of platelet aggregates ( Figure 5 ; Online Video 6). At a shear rate of 250 s Ϫ1 , the number of binding cells decreased to 150 cells/mm 2 platelet aggregate, which indicates sheardependent targeting efficacy. At 500 s Ϫ1 , the binding of MPIOs was reduced significantly; however, we still observed some adherent cells, which bound primarily to larger thrombi (data not shown). To demonstrate the suitability of cell tagging for native human cells, the scFv was also coupled to mononuclear cells isolated from human cord blood using the same conjugation protocol. Online Figure X shows the specific binding of mononuclear cells to thrombi at a shear rate of 250 s Ϫ1 . Finally, intravital microscopy was used to evaluate the targeting of anti-LIBS-coupled cells to activated platelets in mouse mesenteric veins. After the administration of 10ϫ10 6 CHO cells, we noted a significantly higher number of anti-LIBS-conjugated cells binding on the venous thrombi compared with the control (GGG-tagged) cells ( Figure 6 ; Online Videos 7 and 8), which indicates successful in vivo cell targeting with this novel approach.
Discussion
We report a chemoenzymatic method for conjugation of recombinant antibody fragments as targeting ligands to contrast agents and cells, with potential applicability to a broad range of areas including molecular imaging, regenerative cell therapy, and drug delivery. This method combines chemical reactions with a sortase-mediated enzymatic coupling. With eGFP used as a model substrate, optimal enzymatic reaction conditions specific for scFv were established. The scFv was conjugated to MPIOs (contrast agents for MRI) and to model cells (CHO), as well as to human mononuclear cells, with a high efficiency (up to 72%) and preserved scFv bioactivity. The targeting of scFv-coupled contrast particles and cells to activated platelets was demonstrated in vitro with adhesion assays under static and flow conditions. We also successfully demonstrated the retained targeting capability of our conjugation products in vivo. Immediately after injection, we observed strong adhesion of anti-LIBS-conjugated contrast agents at sites of induced thrombi in mesenteric arteries. Furthermore, the suitability of particle tagging for molecular imaging was demonstrated in MRI of carotid artery thrombosis in mice. Finally, sortase-coupled cells could be targeted successfully toward activated platelets on injured endothelium. Overall, this specific targeting approach describes a unique and broadly usable strategy for molecular imaging and cell therapy in thrombotic, atherosclerotic, and inflammatory diseases.
Since the discovery and the isolation of sortase A from S aureus, 8 this enzyme has been used primarily as an engineering tool, eg, to immobilize proteins to solid surfaces such as polystyrene beads, 12 biosensor chips, 16 and microspheres 17 or to synthesize neoglycoconjugates. 18 In addition, recent protein/peptide-protein/peptide oligomerization 12 and labeling of proteins on cells 19 have demonstrated its applicability toward biological use. The present work is the first report of sortase-mediated ligation 
Figure 5. Targeting of scFv-coupled CHO cells to platelet aggregates under shear rates in a flow chamber system after 5 minutes. A, Number of nontargeted cells (GGG cells)
and targeted cells (scFv cells) binding to thrombus under different shear rates (#PϽ0.05, ##PϽ0.01; nϭ3 to 5; Mann-Whitney 1-tailed test) after 5 minutes of perfusion. B and C, Differential interference contrast and fluorescence images show the binding of targeted cells (differential interference contrast images: round gray or white, indicated by green arrows; fluorescence images: green or yellow) on platelet aggregates (differential interference contrast image: white or gray; fluorescence image: red indicates platelet membrane) under shear rates of 100 and 250 s Ϫ1 , respectively. CHO cells were stained with CellTracker. Platelet aggregates formed by the aggregation of activated platelets on collagen-1 fibers were immobilized on the chamber surface and specifically stained with phycoerythrin-labeled anti-CD62P.
of antibodies, or indeed coupling of any targeting protein, and the first demonstration of the in vivo use of the sortase technology. The 2 required short motifs (LPETG and GGG) can be incorporated into substrates of interest either by chemical synthesis or by genetic engineering. We introduced the LPETG motif to anti-LIBS at the C-terminus by polymerase chain reaction cloning while preserving the functionality of the scFv. In addition to their ease of production and limited immunogenicity, scFvs have a structure particularly suitable for sortase-mediated coupling. 20 The C-terminal end is not within the targeting regions of the scFv, thus minimizing the likelihood of compromising the antigen-binding region.
Previously, we have used a noncovalent coupling method between the C-terminal His-tag of the scFv and ion metal groups on MPIOs for molecular MRI. [13] [14] [15] Despite its speed and simplicity, this method is not biocompatible and therefore not suitable for human use. We addressed the challenge of efficient, covalent, and biocompatible conjugation between MPIOs and the anti-LIBS scFv as part of our endeavors to translate the anti-LIBS targeting antibody into a clinical diagnostic imaging product. The robust, specific, and gentle sortase-mediated chemoenzymatic condensation provides a useful alternative to chemical ligation, thereby fulfilling an essential requirement for targeted imaging. Alternative related bioconjugation methods such as native chemical ligation, 21 intein-based ligation, 22 and very few other enzyme-based approaches have been reported. 23 However, these reported methods have common limitations, including the difficulty of synthesizing peptide thioesters, large tags that can lead to expression problems, 24 and an inefficient stepwise ligation procedure. The present MRI data demonstrate that the high signal strength of MPIOs is ideally suited for in vivo MRI in small animals and could be rapidly translated to a clinical setting with biocompatible sortase-mediated bioconjugation. The described method can also be adapted to develop novel targeted radioisotope nanoparticles for molecular positron emission tomography, targeted iodine/gold nanoparticles for computed tomography, and targeted gadolinium nanoparticles for MRI. Targeted positron emission tomography/computed tomography imaging might minimize off-target effects, high background signals, and falsepositive results. Targeted gadolinium nanoparticles would reduce side effects associated with gadolinium nephrotoxicity caused by the targeting approach and thereby lower the injected dose of gadolinium.
The present work is also directly relevant to regenerative stem cell therapy. Despite some promising progress, the full potential of this therapy has not yet been realized. A significant limiting factor is the low grafting efficiency of cells to the target tissue. 25 As demonstrated by the successful targeting of model CHO cells to platelets that adhered to injured endothelium, the described chemoenzymatic approach can specifically direct these cells to the site of disease. Thus, a strong enrichment of desired cells can be achieved. The potential application of this approach for stem cell therapy was also strengthened by the successful binding of mononuclear cells to activated platelets under shear stress in a flow chamber setting.
Our anti-LIBS scFv has a high and specific binding capability to activated GP IIb/IIIa, as demonstrated by the binding of MPIOs in mouse mesenteric and carotid arteries in the present study and by previous reports from our group. [13] [14] [15] 26 Despite providing excellent targeting of smaller particles under arterial shear stress, targeting of CHO cells appears to be restricted to lower shear rates. This can be explained by the fact that CHO cells with a diameter of 10 to 15 m (compared with 1 to 2.7 m for MPIOs) will be subject to higher hemodynamic drag forces than smaller particles. However, leukocyte recruitment and stem cell homing are described as being localized to venules and thus (patho)physiologically take place under low shear conditions. 27, 28 Inflammation (eg, caused by cerebral or myocardial ischemia/reperfusion) results in leukocyte recruitment and stem cell homing at the sites of venules. 29, 30 In addition, in bone marrow, the recruitment site of hematopoietic cells has been found to be the venules, which exhibit a strong expression of adhesion molecules such as vascular cell adhesion molecule-1 and selectins. 31 Therefore, the present findings with antibodytargeted cells are in accordance with the (patho)physiology seen in stem cell homing or leukocyte recruitment with regard to the shear at which these phenomena occur.
Finally, the described method for tagging particles with antibodies is also relevant therapeutically in its application toward targeted drug-delivery vehicles. Nontargeted delivery of therapeutics often requires a high drug load and might cause off-target effects compared with targeted drug delivery. This has been demonstrated for the treatment of several diseases, including cancer 32 and cardiovascular disease. 33 Despite the development of a large number of preclinical delivery systems, very few new technologies or materials have entered clinical trials. One hurdle is that regulatory approval requires well-defined products for clinical use. The first use of a targeted nanoparticle in humans was only recently reported with a phase I clinical trial of a delivery system for small interfering RNA to patients with solid cancers. 34 An efficient bioconjugation method such as sortase-mediated antibody tagging that retains functionality and avoids multicomponent mixtures has the potential to overcome a significant hurdle for a faster and broader translation of targeted drug delivery from bench to bedside.
In conclusion, the present data demonstrate the successful and specific chemoenzymatic conjugation of a recombinant antibody fragment to a reporter protein, contrast agents, and cells with sortase A. This method not only provides an efficient conjugation approach but importantly retains the functionality of the targeting antibody component and avoids heterogeneous multilabeled mixtures. The utility of this approach is potentially very broad, with the conjugation of any triglycine-containing substrate/cell/ particle to any LPETG-containing substrate/cell/particle. Both LPETG and GGG are unique, thereby providing highly specific coupling. More specifically, this work establishes sortase-mediated bioconjugation as a potentially universal and versatile technique for antibodytargeted molecular imaging and regenerative cell therapy.
Novelty and Significance
What Is Known?
• Targeted delivery can be achieved via the use of specific binding ligands, such as antibodies. • Currently, binding ligands are conjugated primarily to therapeutic/ imaging agents via chemical methods, which are not site specific and typically result in impaired ligand binding (eg, reduced antibody affinity), low product yields, and multicomponent mixtures. • Some site-specific conjugation approaches have been reported, but they have practical limitations in terms of feasibility, scalability, and efficacy.
What New Information Does This Article Contribute?
• The article reports on a versatile and universally applicable sitespecific conjugation method for targeted regenerative cell therapy and targeted molecular imaging in cardiovascular and inflammatory diseases.
We have developed a new, robust, and highly reproducible chemoenzymatic approach to obtain site-specific conjugation that preserves functionality of the binding ligands. With this method, an activation-specific antiplatelet single-chain antibody was successfully conjugated to a model protein, a magnetic resonance imaging agent, and 2 model cells, with high efficiency and good yield. The antibody-coupled products were targeted to activated platelets in both in vitro and in vivo settings in a specific and efficient manner. Our work is the first report of sortase-mediated ligation of antibodies, or indeed coupling of any targeting protein, and the first demonstration of in vivo use of the sortase technology. The method we have developed provides an efficient conjugation approach that retains the functionality of the targeting antibody component and avoids heterogeneous multilabeled mixtures. This unique biotechnological approach can be generalized to conjugate any antibody or other binding ligands to any triglycine containing substrates for targeting purposes.
